Pre-made Siplizumab benchmark antibody (Whole mAb, anti-CD2 therapeutic antibody, Anti-LFA-2/SRBC/T11 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-CD2 therapeutic antibody (Pre-made Siplizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Siplizumab (MEDI-57) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]
| Products Name (INN Index) | Pre-Made Siplizumab Biosimilar, Whole Mab, Anti-Cd2 Antibody: Anti-LFA-2/SRBC/T11 therapeutic antibody |
|---|---|
| INN Name | siplizumab |
| Target | CD2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | BioTransplant (Charlestown MA USA) / MedImmune (Gaithersburg MD USA) / AstraZeneca (London UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD2 |
| Package |
